Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Official Title

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Summary:

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

Trial Description

Primary Outcome:

  • To efficiently identify based on objective response rate (ORR), using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized trials
Secondary Outcome:
  • Evaluate ORR using RECIST 1.1
  • Determine progression-free survival of immunotherapy regimens (RECIST 1.1 and iRECIST)
  • Determine overall-survival of immunotherapy regimens (RECIST 1.1 and iRECIST)
  • Number and severity of adverse events
This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society